Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study
Background There is little evidence on the relationship between statin use and the risk of hospitalization attributable to COVID‐19. Methods and Results The French National Healthcare Data System database was used to conduct a matched‐cohort study. For each adult aged ≥40 years receiving statins for...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.121.023357 |
| _version_ | 1797301691700215808 |
|---|---|
| author | Kim Bouillon Bérangère Baricault Laura Semenzato Jérémie Botton Marion Bertrand Jérôme Drouin Rosemary Dray‐Spira Alain Weill Mahmoud Zureik |
| author_facet | Kim Bouillon Bérangère Baricault Laura Semenzato Jérémie Botton Marion Bertrand Jérôme Drouin Rosemary Dray‐Spira Alain Weill Mahmoud Zureik |
| author_sort | Kim Bouillon |
| collection | DOAJ |
| description | Background There is little evidence on the relationship between statin use and the risk of hospitalization attributable to COVID‐19. Methods and Results The French National Healthcare Data System database was used to conduct a matched‐cohort study. For each adult aged ≥40 years receiving statins for the primary prevention of cardiovascular diseases, one nonuser was randomly selected and matched for year of birth, sex, residence area, and comorbidities. The association between statin use and hospitalization for COVID‐19 was examined using conditional Cox proportional hazards models, adjusted for baseline characteristics, comorbidities, and long‐term medications. Its association with in‐hospital death from COVID‐19 was also explored. All participants were followed up from February 15, 2020, to June 15, 2020. The matching procedure generated 2 058 249 adults in the statin group and 2 058 249 in the control group, composed of 46.6% of men with a mean age of 68.7 years. Statin users had a 16% lower risk of hospitalization for COVID‐19 than nonusers (adjusted hazard ratio [HR], 0.84; 95% CI, 0.81–0.88). All types of statins were significantly associated with a lower risk of hospitalization, with the adjusted HR ranging from 0.75 for fluvastatin to 0.89 for atorvastatin. Low‐ and moderate‐intensity statins also showed a lower risk compared with nonusers (HR, 0.78 [95% CI, 0.71–0.86] and HR, 0.84 [95% CI, 0.80–0.89], respectively), whereas high‐intensity statins did not (HR, 1.01; 95% CI, 0.86–1.18). We found similar results with in‐hospital death from COVID‐19. Conclusions Our findings support that the use of statins for primary prevention is associated with lower risks of hospitalization for COVID‐19 and of in‐hospital death from COVID‐19. |
| first_indexed | 2024-03-07T23:26:15Z |
| format | Article |
| id | doaj.art-ef620744b554447f968e1d0aa1a27187 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-03-07T23:26:15Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-ef620744b554447f968e1d0aa1a271872024-02-21T04:31:45ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802022-06-01111210.1161/JAHA.121.023357Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort StudyKim Bouillon0Bérangère Baricault1Laura Semenzato2Jérémie Botton3Marion Bertrand4Jérôme Drouin5Rosemary Dray‐Spira6Alain Weill7Mahmoud Zureik8EPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceEPI‐PHARE Scientific Interest Group in Epidemiology of Health Products Saint‐Denis FranceBackground There is little evidence on the relationship between statin use and the risk of hospitalization attributable to COVID‐19. Methods and Results The French National Healthcare Data System database was used to conduct a matched‐cohort study. For each adult aged ≥40 years receiving statins for the primary prevention of cardiovascular diseases, one nonuser was randomly selected and matched for year of birth, sex, residence area, and comorbidities. The association between statin use and hospitalization for COVID‐19 was examined using conditional Cox proportional hazards models, adjusted for baseline characteristics, comorbidities, and long‐term medications. Its association with in‐hospital death from COVID‐19 was also explored. All participants were followed up from February 15, 2020, to June 15, 2020. The matching procedure generated 2 058 249 adults in the statin group and 2 058 249 in the control group, composed of 46.6% of men with a mean age of 68.7 years. Statin users had a 16% lower risk of hospitalization for COVID‐19 than nonusers (adjusted hazard ratio [HR], 0.84; 95% CI, 0.81–0.88). All types of statins were significantly associated with a lower risk of hospitalization, with the adjusted HR ranging from 0.75 for fluvastatin to 0.89 for atorvastatin. Low‐ and moderate‐intensity statins also showed a lower risk compared with nonusers (HR, 0.78 [95% CI, 0.71–0.86] and HR, 0.84 [95% CI, 0.80–0.89], respectively), whereas high‐intensity statins did not (HR, 1.01; 95% CI, 0.86–1.18). We found similar results with in‐hospital death from COVID‐19. Conclusions Our findings support that the use of statins for primary prevention is associated with lower risks of hospitalization for COVID‐19 and of in‐hospital death from COVID‐19.https://www.ahajournals.org/doi/10.1161/JAHA.121.023357COVID‐19hospitalizationmortalitySARS‐CoV‐2statins |
| spellingShingle | Kim Bouillon Bérangère Baricault Laura Semenzato Jérémie Botton Marion Bertrand Jérôme Drouin Rosemary Dray‐Spira Alain Weill Mahmoud Zureik Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease COVID‐19 hospitalization mortality SARS‐CoV‐2 statins |
| title | Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study |
| title_full | Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study |
| title_fullStr | Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study |
| title_full_unstemmed | Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study |
| title_short | Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study |
| title_sort | association of statins for primary prevention of cardiovascular diseases with hospitalization for covid 19 a nationwide matched population based cohort study |
| topic | COVID‐19 hospitalization mortality SARS‐CoV‐2 statins |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.121.023357 |
| work_keys_str_mv | AT kimbouillon associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT berangerebaricault associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT laurasemenzato associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT jeremiebotton associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT marionbertrand associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT jeromedrouin associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT rosemarydrayspira associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT alainweill associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy AT mahmoudzureik associationofstatinsforprimarypreventionofcardiovasculardiseaseswithhospitalizationforcovid19anationwidematchedpopulationbasedcohortstudy |